MiniMed

What MiniMed does

MiniMed Group, Inc. (Nasdaq: MMED) is a global diabetes technology company headquartered in Northridge, California, that spun off from Medtronic plc via IPO in March 2026, with Medtronic retaining approximately 90% ownership and full separation expected within six months. The company develops and markets integrated diabetes management systems serving more than 640,000 insulin pump users across over 80 countries, targeting people with type 1 diabetes, insulin-requiring type 2 diabetes, and multiple daily injection users. Its product portfolio centers on three integrated platforms: the MiniMed 780G automated insulin delivery system (flagship pump powered by the SmartGuard adaptive algorithm with Meal Detection technology, achieving 80% Time in Range in real-world evidence), the MiniMed Flex (smallest pump at roughly half the size of legacy devices, first smartphone-controlled, FDA-cleared March 2026 and commercially launched June 2026), and the MiniMed Go smart insulin pen system for the MDI population (U.S. launched June 2026). These systems integrate with MiniMed's Simplera Sync disposable CGM and Abbott's Instinct CGM (15-day wear time, CE Mark March 2026) via the sensor-agnostic 780G algorithm, positioning MiniMed as the only player offering a complete insulin management ecosystem.

The company's business model is anchored by a high-recurring revenue base: approximately 83% of revenue derives from consumables (sensors, reservoirs, infusion sets), software, and services layered on top of durable pump hardware. MiniMed generated $3.102 billion in FY26 net sales (14.2% year-over-year growth), with international sales surging 22.4% in Q4 FY26 driven by Simplera capacity expansion. Go-to-market relies on enterprise field sales through endocrinologist and diabetes specialist networks, pharmacy/DME distribution channels for consumables, and clinical engagement at major conferences (ADA Scientific Sessions, ATTD). FY27 guidance targets approximately 10% organic revenue growth and ~16% adjusted EBITDA margin. The company employs 8,000+ people and completed its IPO at a $5.35–5.62 billion valuation, raising approximately $538–560 million in net proceeds, with management citing upcoming U.S. Medicare channel entry, the European Instinct-integrated 780G rollout, and a planned fall 2026 FDA submission for MiniMed's first insulin patch pump as the principal near-term growth catalysts.

Name

MiniMed

Legal name

MiniMed Group, Inc.

Website

https://minimedpanama.com

Company type

Public

Founded year

2026

Operating status

Ipo

Headcount range

5,001–10,000 employees

Short description

MiniMed (Nasdaq: MMED) is a global diabetes technology company spun off from Medtronic that develops automated insulin delivery systems, CGM sensors, and smart insulin pens. It serves over 640,000 insulin pump users in 80+ countries with its 780G, Flex, and Go platforms.

Ownership category

akta.pro rank

Product category

Diabetes Management Devices

SIC

Orthopedic, Prosthetic & Surgical Appliances & Supplies (3842)

akta.pro primary industry

Automated Insulin Delivery (AID) / Closed-Loop Systems (HLAHAHAF)

akta.pro secondary industries

Insulin Pumps (Tubed) (HLAHAHAB), Patch Pumps & Wearable Insulin Delivery (HLAHAHAC), Diabetes Digital Therapeutics & Dose Decision Support (Bolus Calculators) (HLAHAHAJ), Insulin Pen Needles, Syringes & Infusion Sets (Consumables) (HLAHAHAE), Diabetes Care Device Accessories & Adhesives (Sensors/Pump Supplies) (HLAHAHAL), Type 1 Diabetes Care (HLAKADAB)

Keywords

• Insulin pump systems
• Continuous glucose monitoring
• Automated insulin delivery
• Diabetes management devices
• Smart insulin pen

Headquarters

HQ city

Ciudad De Panamá

HQ country

Panama

HQ region

Latin America

Offices1 record

Markets served

GTM type

B2C

Offering type

Hardware or Manufacturing

Cost components

Operations, Supply Chain, Technology or R&D, Personnel, Marketing or Sales

Revenue model

1. Insulin Delivery Systems and Consumables: MiniMed generates approximately 83% of its revenue from consumables, software, and services. The company offers a complete insulin management ecosystem including pumps, sensors, and smart insulin pens.
2. MiniMed Go System: Smart insulin pen system for multiple daily injections launched in the US market, representing the company's expansion into broader diabetes management beyond traditional insulin pump users.
3. International Markets: International sales surged 22.4% to $599 million in Q4 FY26 driven by Simplera capacity expansion, with CE Mark approvals expanding European market presence.

Pricing tiers

Go-to-market motion3 records

Distribution channels3 records

Marketing channels4 records

Core offering

MiniMed manufactures and sells integrated diabetes management systems, including automated insulin delivery pumps (MiniMed 780G, MiniMed Flex), continuous glucose monitoring sensors (Simplera Sync), and smart insulin pens (MiniMed Go). The flagship MiniMed 780G system uses the proprietary SmartGuard algorithm with Meal Detection technology to automatically adjust insulin delivery every five minutes based on real-time CGM data, targeting approximately 80% Time in Range for users with Type 1 and insulin-requiring Type 2 diabetes.

Product overview

MiniMed (Nasdaq: MMED) is a global diabetes technology company spun off from Medtronic via IPO in March 2026, operating in more than 80 countries with over 40 years of experience in insulin delivery systems. The company positions itself as the only player offering a complete insulin management ecosystem. Its product portfolio centers on three integrated insulin delivery platforms: the MiniMed 780G automated insulin delivery system (the flagship pump with SmartGuard algorithm), the MiniMed Flex (the smallest, first app-controlled pump launched in June 2026), and the MiniMed Go smart insulin pen system for multiple daily injections. These systems integrate with MiniMed's own Simplera Sync CGM sensor and Abbott's Instinct CGM sensor (the world's smallest/thinnest 15-day sensor) via the SmartGuard algorithm, which uses predictive analytics to automate insulin dosing. The portfolio generates approximately 83% of revenue from consumables, software, and services. MiniMed surpassed $3 billion in annual revenue in fiscal year 2026 and targets approximately 10% organic revenue growth for fiscal year 2027.

Differentiator

Problem solved

Functional benefit

Products and services

• MiniMed 780G Automated Insulin Delivery System

Quantifiable outcome

• 80% Time in Range achieved by MiniMed 780G users
• +3 more outcomes

Named customers1 record

Segments4 records

Ideal customer profiles2 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Integration2 records

AI capability3 records

Feature5 records

Partnerships

Three partnerships are on record, tiered core.

• Abbott LaboratoriescoreTechnology or Integration · 3 June 2026MiniMed expanded partnership with Abbott to co-develop dual glucose-ketone sensors for MiniMed's smart dosing systems. The partnership builds on Abbott's existing exclusive Instinct continuous glucose monitor collaboration. Abbott recently received CE Mark for its dual glucose-ketone system, which is also under FDA review. Commercial and regulatory milestones expected in coming months.
• Abbott (Instinct Sensor)coreTechnology or Integration · 24 February 2026Exclusive partnership for Abbott's Instinct CGM sensor integration with MiniMed systems. The Instinct sensor is the world's smallest, thinnest integrated CGM offering up to 15 days of wear compared to existing 7-day options. CE Mark approved March 2026 for MiniMed 780G system integration.
• MedtroniccoreStrategic or Co-development PartnerMiniMed completed IPO in March 2026 as Medtronic's diabetes business spinoff. Medtronic remains the majority shareholder with approximately 90% ownership. The split-off is expected to complete approximately six months after the IPO, nearly 25 years after Medtronic acquired the business for nearly $3.3 billion. Medtronic designated Linnea Burman to serve on MiniMed's board.

Scale indicators10 records

Recent moves3 records

Expansion highlights6 records

Emerging players

• Ypsomed: Ypsomed sells the mylife YpsoPump and partners with Dexcom for CGM-integrated AID in Europe, making it a direct European pump competitor to MiniMed's 780G and Instinct-integrated systems.
• LifeScan: LifeScan is a focused diabetes management player (OneTouch blood glucose monitoring) that competes at the consumer/diagnostics layer adjacent to MiniMed's broader diabetes ecosystem.
• Embecta: Embecta was spun off from BD as a pure-play diabetes injection device company, competing with MiniMed Go in the smart insulin pen and MDI segment, particularly in Type 2 diabetes.
• Bigfoot Biomedical: Bigfoot Unity is a connected insulin pen system targeting MDI users, an emerging AID and smart pen player with overlapping use cases to MiniMed Go.
• Beta Bionics: Beta Bionics markets the iLet bionic pancreas, an automated insulin delivery system that competes with MiniMed 780G and Flex in the AID category, particularly for users seeking fully autonomous dosing.

Broad incumbents

• Roche Diabetes Care: Roche is a broad incumbent in diabetes (Accu-Chek meters, insulin delivery systems, digital diabetes management) with a global footprint that overlaps with MiniMed's, though it is less focused on AID pumps.

Direct peers

• Dexcom: Dexcom is the leading standalone continuous glucose monitor (G7) and a direct competitor to MiniMed's Simplera Sync sensor as well as a partner/competitor to Abbott; CGM performance is central to MiniMed's AID outcomes.
• Insulet Corporation: Insulet is the leading tubeless patch pump maker (OmniPod) and the most direct competitor to MiniMed in automated insulin delivery, particularly given Insulet's entrenched position in the patch-pump segment MiniMed is only now entering.
• Tandem Diabetes Care: Tandem sells the t:slim X2 insulin pump and Control-IQ AID system, competing head-to-head with MiniMed 780G in the US Type 1 diabetes pump market and pushing similar automated insulin delivery features.
• Abbott Diabetes Care: Abbott's FreeStyle Libre franchise is the dominant CGM globally and a competitor to MiniMed's Simplera Sync, even as Abbott simultaneously serves as MiniMed's exclusive partner for Instinct and dual glucose-ketone sensors.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat6 records

Key risks6 records

Key highlights7 records

Customer concentration

• Xx.com/MiniMedPa
• Facebookfacebook.com/minimedpanama
• LinkedInlinkedin.com/company/minimed-panama

Revenue estimate

Valuation estimate

Number of profiles

Profiles4 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about MiniMed